PROTEINASE-ACTIVATED RECEPTOR-2 (PAR 2 ) is a G protein-coupled receptor (GPCR) that is activated via cleavage of its NH 2 terminus by serine proteinases including trypsin, mast cell tryptase, kallikreins, membrane-type serine proteinase 1, and the tissue factor VIIa-Xa complex (5, 14, 17, 29, 37, 48) . Proteolytic cleavage of the NH 2 -terminal domain exposes a tethered ligand that binds and activates the receptor itself. PAR 2 is reported to trigger a wide variety of cellular responses (e.g., proliferation, chemotaxis, ion transport, epithelial barrier function, and tumor cell metastasis) in a cell type-specific manner (30, 40) . In vitro, peptides corresponding to the tethered ligand (SLIGRL/KV-NH 2 ) and synthetic analogs of tethered ligand peptides, such as 2-furoyl-LIGRL-O-NH 2 (2fAP) can activate PAR 2 and trigger downstream signals in the absence of proteolytic cleavage (2, 30, 43) . Previous studies have established that activation of PAR 2 can evoke both proand antiinflammatory responses in the intestine, including vasodilation, smooth muscle relaxation, cytokine upregulation, immune cell recruitment, and increased nociception and hyperalgesia (7, 8, 12, 23, (31) (32) (33) .
Here we examined the roles of apical and basolateral PAR 2 in intestinal epithelial cells. Studies that used PAR 2 -specific antibodies or conducted intracolonic administration of fluorescently conjugated 2fAP suggested that intestinal epithelial cells (both in vivo and in various cell culture lines) express PAR 2 on both the apical and basolateral surfaces (14, 30, 37) . Furthermore, expression of basolateral PAR 2 at the perijunctional margin of human colonic mucosa was reported to be increased in patients with Crohn's disease, and its expression correlated with a neutrophil-mediated decrease in transepithelial resistance (12) . However, the accessibility of each receptor pool to agonists and the corresponding downstream signaling and physiological responses, to either basolateral or apical receptor activation, have not yet been clarified. Studies suggest that basolateral PAR 2 can be activated by mast cell tryptase or proteinases released by recruited leukocytes (14, 33, 50) , while apical receptor can be activated by trypsin (either pancreatic or secreted by the enterocytes) or by luminal proteinases released by invading pathogens (12, 18, 28, 33, 34, 37) . Many of these studies suggest that inflammatory responses in the intestine can be induced by luminal introduction of PAR 2 -activating peptides and by serosal exposure to mast cell tryptase. While the specific cellular responses such as ion secretion and changes in transepithelial electrical resistance (R T ) have been reported in response to basolaterally administered agonist in cultured cells (19, 41, 45, (51) (52) (53) , little is known about signaling via apical PAR 2 . Furthermore, the possibility that there are distinctions in signaling between the apical and basolateral receptor populations has not yet been addressed. This is a particularly pertinent question given the recent evidence that PAR 2 is capable of signaling through multiple independent pathways, involving G protein-dependent and ␤-arrestin-dependent events, leading to a diverse array of physiological responses (44, 54, 55, 57, 58) . Here we examine the following: 1) whether apical and basolateral PAR 2 are accessible to labeled 2fAP in polarized intestinal epithelial monolayers (Caco2-BBe); 2) whether there are temporal and mechanistic distinctions in apical and basolateral PAR 2 signaling; and 3) whether either pool uses ␤-arrestindependent signaling pathways.
MATERIAL AND METHODS
All chemicals were from Sigma unless otherwise stated. Antibodies and final dilutions for Western blot (WB) and immunofluorescence (IF) analysis were as follows: from BD Biosciences, mouse monoclonal anti-cofilin (1:1,000 for WB) and mouse monoclonal anti-zona occludin 1 (ZO-1) (1:500 IF); from Cell Signaling, rabbit anti-phospho (Ser3)-cofilin (1:1,000 for WB); rabbit anti-phospho (Thr202/Tyr204)-ERK (1:1,000 for WB, 1:500 for IF); and mouse anti-ERK1/2 (1:1,000 for WB). Rabbit anti-PAR 2 9717 (1:300 for IF), raised against a peptide corresponding to the COOH terminus of mouse PAR 2 (SVKTSY) and characterized previously (14) , was obtained from the Center for Ulcer Research and Education (University of California Los Angeles). Alexa Fluor 488-labeled phalloidin (1:20 IF) was from Invitrogen. Activating peptides 2fAP (2-furoyl-LIGRL-ornithine-NH 2), rhodamine-labeled 2fAP and reverse 2fAP (2-furoyl-LRGILornithine-NH 2) were synthesized by Genemed (South San Francisco, CA). Pharmacological inhibitors were used as follows: Ca 2ϩ chelator BAPTA-AM (Sigma) was prepared in dimethyl formamide, diluted to 10 mM in DMSO and used at 30 M final concentration; PLC inhibitor U73122 (Tocris) was solubilized in chloroform, diluted to 100 mM in DMSO immediately before use at 1 M final concentration; PKC inhibitor GF109203X (Tocris) was solubilized at 25 mM in DMSO and used at 1 M final concentration. Dominant-negative ␤-arrestin-1, corresponding to amino acids 319 -418, was a gift from Dr. Robert Lefkowitz (Duke University Medical School, Durham, NC).
Transfection and cell lines. A human intestinal colon carcinoma cell line, selected for brush border formation (Caco2-BBe), was obtained from Dr. David Lo (University of California, Riverside) and grown in advanced Dulbecco's modified Eagle's medium, 15 mM HEPES, and 10% fetal calf serum. Transient transfections were performed on 95% confluent cells using FuGENE6 (Roche), and experiments were performed between 48 and 72 h after transfection. For other experiments, Caco2-BBe cells stably transfected with a luciferase reporter construct in which luciferase transcription is controlled by three AP-1 binding sites and a TATA box cloned upstream from the luciferase gene (42) . To accomplish this, the AP-1-luciferase reporter was cotransfected into Caco2-BBe cells along with pRSVneo. The transfected cells were cultured in medium containing 400 g/ml G418, and neomycin-resistant clones were pooled to create a cell line stably transfected with the reporter. The transfection and assays of luciferase activity were performed as described previously (39) .
PAR2 labeling with rhodamine-2fAP. Caco2-BBe cells were seeded on permeable supports (Costar Snapwell, 24 well, 0.4 m pore) at 2 ϫ 10 4 cells per well and grown for 10 -14 days to confluence. After the monolayers attained a resistance of 750 ⍀/cm 2 (Epithelial Voltohmmeter, WPI, Sarasota, FL), they were exposed to 1 M rhodaminelabeled 2fAP or RAP at 4°C for 1 h, or at 4°C for 1 h then 37°C for 1 h. The cells were rinsed three times with ice-cold sterile phosphatebuffered saline solution (PBS) to remove unbound label, and then fixed in neutral buffered formalin (Fisher) on ice for 1 h. Fixed cells were labeled with Alexa Fluor 488-phalloidin.
Protein analysis and Western blotting. Caco2-BBe cells were seeded on permeable supports (Costar Snapwell, 6 well, 0.4 m pore) at 5 ϫ 10 4 cells per well, then starved of serum for 24 h. Where indicated, inhibitors were added to both apical and basolateral compartments at the concentrations indicated above for 10 min. Vehicle controls were preincubated with DMSO alone. Monolayers were exposed to 1 M 2fAP on the apical or basolateral surface for 0 -60 min at 37°C, then solubilized in Laemmli sample buffer [62.5 mM Tris·HCl (pH 6.8), 2% (wt/vol) sodium dodecyl sulfate, 50 mM dithiothreitol, and 0.01% (wt/vol) bromophenol blue]. Protein was analyzed by SDS-PAGE (15% for cofilin, 10% for ERK1/2) followed by WB. Blots were imaged using the LICOR Odyssey imaging system, and LICOR software was used to calculate integrated intensities of bands. Images of WB were assembled using Adobe Photoshop 5.0 and Adobe Illustrator CS4. Some gels were spliced to eliminate blank lanes or lanes containing samples unrelated to the figure.
Electrical measurements. The short-circuit current (Isc) and RT across confluent Caco2-BBe monolayers grown on permeable supports (Costar Snapwell, 6 well, 0.4 m pore) were measured using a conventional Ussing chamber technique, as described previously (3) . Snapwell inserts were incubated in chambers (EM-CSYS-2, Physiologic Instruments) containing Tyrode solution (140 mM NaCl, 4 mM KCl, 1 mM MgCl 2, 1.25 mM CaCl2, 12 mM glucose, and 10 mM Na-HEPES, pH 7.4) mixed continuously by gas (100% O2) lift. Chambers were maintained at 37°C by heated water jackets. Once the resting Isc stabilized (10 min), the changes in Isc and RT after sequential addition of 1 M of 2fAP to the luminal and serosal compartments were recorded.
Microscopy. Confluent Caco2-BBe monolayers were fixed and imaged as described previously (26) . Serial sections were taken on Zeiss LSM-510 using ϫ63 or ϫ100 objectives. Three-dimensional reconstructions of the images were done using Imaris 6.3 software.
Immunolabeling of PAR 2 in ileum. Four-month-old female wildtype C57Bl6 mice (Jackson Labs) and PAR 2 Ϫ/Ϫ mice in a C57Bl6 background (from Dr. Robin Plevin, University of Strathclyde, Glasgow, UK) were used for immunofluorescent labeling. All animal protocols were approved by the Institutional Animal Care and Use Committee of University of California, Riverside. Mice were euthanized, and short segments of mouse ileum were fixed in ice-cold formalin for 5 h, infiltrated with cryoprotectant (30% sucrose in PBS) overnight, and frozen in OTC medium (Triangle Biomedical Sciences) at Ϫ35°C. Sections of 10 m thickness were cut on a cryostat microtome (Microm) and mounted on polylysine-coated glass slides (Fisher Superfrost Plus). Sections were incubated sequentially with blocking solution (1 h), primary antibody (overnight at 4°C), and secondary antibodies conjugated to Alexa Fluor-488 and/or -546 (Molecular Probes). Antibody-9717 against mouse PAR 2 proved suitable for use with undenatured sections but not with sections subjected to antigen unmasking with either heat or SDS. When colabeling with mouse monoclonal antibody against ZO-1, endogenous mouse IgG was blocked by preincubation in goat anti-mouse IgG for 1 h. Confocal images were acquired with a Zeiss LSM-510 microscope and assembled using Adobe Photoshop.
Barbed end labeling. Caco2 monolayers plated on collagen-coated Transwell inserts, or mouse ileum sections were prepared as described above and treated with 2fAP for 5 min. 2fAP administration was restricted to the basolateral surface of Caco2 monolayers as described above. It was not possible to restrict 2fAP administration to the basolateral surface of mouse ileum, so tissue sections were bathed in 2fAP containing solution. Media were immediately exchanged for actin monomer buffer [20 mM HEPES, pH 7.5, 138 mM KCl, 4 mM MgCl 2, 3 mM EGTA, 0.2 mg/ml of saponin, 1 mM ATP, 1% BSA, and 0.3 M rhodamine-labeled G-actin (from Cytoskeleton, Boulder, CO)], and cells were incubated for 1 min to allow incorporation of labeled monomers into cells. Cells/tissue were washed in 0.1 M glycine-PBS for 10 min, then fixed, stained, and imaged as described in Microscopy.
Data and statistical analysis. All graphs and statistical analysis were performed using Prism or Microsoft Excel 2003. All experiments were performed a minimum of three times. Phosphoprotein levels were normalized to total protein levels before calculation of fold change with respect to untreated controls. One-way ANOVA and two-tailed Tukey t-tests were used to determine statistical significance of and significant differences between values under different conditions. 2 in polarized Caco2-BBe monolayers. Serine proteinases released by neutrophils and mast cells can activate PAR 2 in the intestinal epithelium evoking inflammation, and administration of PAR 2 agonists to the serosal side of epithelial monolayers promotes Ca 2ϩ mobilization and ion secretion (15, 19, 33) , suggesting that basolateral PAR 2 is also accessible to agonists in the interstitial space and blood. Studies have also shown that PAR 2 activating peptides administered intracolonically can bind PAR 2 and trigger inflammatory responses (7, 8, 30) , suggesting apical PAR 2 is expressed on the cell surface and accessible to peptide agonist. However, it is formally possible that process of administering the peptide compromised the epithelium, allowing access of peptide agonists to the serosa. Thus, we examined the surface accessibility of apical and basolateral PAR 2 in polarized colonic epithelial cell monolayers (Caco2-BBe) grown on permeabilized supports. The integrity of the cell monolayer was confirmed by measuring R T ; only monolayers with R T Ͼ 750 ⍀/cm 2 were used in subsequent experiments. Rhodamine-labeled PAR 2 agonist peptide (2-furoyl-LIGRL, Rh-2fAP) was administered to either the apical or the basolateral compartment for 1 h, and cells were held at 0°C to prevent receptor trafficking, after which they were fixed and stained with antibody to ZO-1 to mark tight junctions. Confocal fluorescence microscopy revealed that apically administered Rh-2fAP bound the surface of the epithelial monolayers ( Fig. 1, A and B) , whereas an inactive control peptide (2-furoyl-LRGIL, Rh-RAP) did not, indicating that the signal is not due to nonspecific binding of labeled peptides (Fig. 1, C and D) . No significant Rh-2fAP was detected in the lower chamber after apical administration, as determined by measurement of absorbance of media in a microplate reader (absorbance ϭ 546 nm), confirming that no leakage across the monolayers occurred. Three-dimensional reconstruction of Z sections revealed that apical PAR 2 was localized in the same plane as the tight junctions, consistent with their presence on the apical surface (Fig. 1I ). Since PAR 2 agonist peptides promote removal of receptor from the surface by clathrinmediated receptor endocytosis (22), we next investigated whether the labeled peptide was internalized along with PAR 2 . After monolayers were warmed to 37°C, Rh-2fAP (Fig. 1, E  and F) , but not Rh-RAP (Fig. 1, G and H) , was observed in vesicles below the region demarcated by the ZO-1 (Fig. 1J) . Basolaterally administered Rh-2fAP labeled PAR 2 along the basolateral membrane, a pool of receptor not labeled by apically applied agonist (Fig. 2, A-D, I ). When cells were warmed to 37°C, bound Rh-2fAP peptide was internalized (Fig. 2 , E-H, J). Interestingly, when the cells were warmed to 37°C in the presence of Rh-2fAP, ZO-1 redistributed from the tight junc- Fig. 1 . Labeling of apical proteinase-activated receptor-2 (PAR2) with rhodamine-2-furoyl-LIGRL-O-NH2 (Rh-2fAP) in polarized Caco2-BBe monolayers. A-D: Caco2-BBe monolayers were labeled with apically administered Rh-2fAP (A and B) or a rhodamine-labeled negative control peptide, 2-furoyl-LRGIL (Rh-RAP) (C and D). Cells were fixed and stained with antibody for tight junction protein zona occludin-1 (ZO-1) to demarcate the apical surface. E-H: to monitor internalization, Rh-2fAP (E and F) and Rh-RAP (G and H)-labeled cells were warmed to 37°C for 1 h. I and J: three-dimensional reconstruction of the microscopy images via Imaris software further shows labeling of apical PAR2 with Rh-2fAP on the apical membrane surface (I) and PAR2-induced internalization at 37°C (J).
RESULTS

Expression of accessible apical and basolateral PAR
tions to an intracellular pool below the apical plane (Table 1) . This effect on ZO-1 was not observed with the inactive control peptide (Fig. 2) . We conclude that both apical and basolateral pools of PAR 2 exist, and both are expressed on the cell surface as they are both accessible to agonist. Furthermore, while basolateral PAR 2 activation promotes redistribution of tight junction proteins from the membrane to the cytoplasm, apical administration does not.
These experiments using cultured cells suggest that PAR 2 could be present at both the apical and basolateral surfaces in vivo. To evaluate this possibility, we examined the distribution of PAR 2 in mouse terminal ileum by confocal immunofluorescence microscopy. We observed labeling primarily at the brush border of villus enterocytes, and weaker labeling of the lateral membrane and submucosal nerve plexi (Fig. 3, left) , confirming previous reports (16) . No such labeling was observed in identically processed segments of ileum from PAR 2 knockout mice, confirming the specificity of antibody-9717 (Fig. 3,  right) .
Basolateral PAR 2 activation evokes electrogenic Cl Ϫ secretion in Caco2-BBe. Studies on intestinal mucosa have demonstrated that basolateral, but not apical, activation of PAR 2 promotes Cl Ϫ secretion in distal colonic mucosa and cultured cell lines (19, 51) . We first confirmed this result in Caco2-BBe monolayers. As shown in Fig. 4 Values are means Ϯ SE. Caco2-Bbe monolayers, treated with rhodamine 2-furoyl-LIGRL-O-NH2 (2fAP) and maintained on ice or warmed to 37°C for 1 h, as described in Figs. 1 and 2 , were analyzed by confocal microscopy, and three-dimensional images were reconstructed using Imaris software. The numbers of zona occludin-1 (ZO-1) fluorescent vesicles, Ͼ50 nM, were quantified, and the numbers of vesicles located 5 m below the apical surface are presented. Measurements were taken from 10 images from 2 independent experiments. PAR2, proteinase-activated receptor 2; RAP, 2-furoyl-LRGIL. ‫ء‬Number of ZO-1-positive fluorescent spheres Ն5 m below apical surface. †Significantly greater than RAP treated, P ϭ 0.01; ‡significantly greater than 2fAP apical, P ϭ 0.005. after a brief (ϳ1.5 min) delay, whereas serosal 2fAP produced a reduction in R T that was (as expected) temporally correlated with the induced secretory current (Fig. 4B) . We conclude that, in contrast to basolateral PAR 2 , apical PAR 2 is not coupled to the Cl Ϫ secretory mechanism. Apical and basolateral PAR 2 promote temporally and mechanistically distinct pathways of ERK1/2 activation. Studies dissecting the molecular mechanism of PAR 2 -stimulated ion transport in colonic epithelial cells revealed a complex mechanism involving G␣q/Ca 2ϩ -dependent activation of selective PKC isoforms, transactivation of EGF receptor (EGFR), ERK1/2 activation leading to prostaglandin E2 (PGE 2 ) release and subsequent activation of the G␣s/cAMP-coupled PGE 2 receptor (51-53). EGFR transactivation and subsequent activation of ERK1/2 is a mechanism shared by other Ca 2ϩ -dependent Cl Ϫ secretory pathways in the intestine (36) and PAR 2 is capable of activating ERK1/2 by multiple mechanisms, leading to distinct cellular responses (21, 25, 33, 38, 44) . Whether all of these pathways exist sequentially or represent independent mechanisms for promoting Cl Ϫ secretion is not clear. We first investigated whether both receptor pools were capable of activating ERK1/2 and whether they utilized the same signaling pathways to do so. After introduction of 2fAP to the apical or basolateral side of Caco2-BBe monolayers grown on permeabilized supports (Fig. 5, A and B, respectively) , we observed a temporal difference in the activation of ERK1/2, as determined by Western blot analysis with antiphospho-ERK. Apical administration of 2fAP promoted a biphasic increase in ERK1/2 phosphorylation, peaking at 5 min (4.86 Ϯ 0.70-fold over baseline), decreasing at 30 min, and peaking again at 60 min (3.49 Ϯ 0.36-fold over baseline). In contrast, basolateral 2fAP promoted a slow and prolonged ERK1/2 activation reaching 6.20 Ϯ 0.96-fold change over baseline by 60 min. We conclude that both receptor pools are capable of signaling to the ERK1/2 pathway.
To determine which signaling pathways were utilized by each receptor pool, we repeated ERK1/2 phosphorylation assays in the presence of inhibitors the classical G␣q signaling pathway which results in activation of PLC␤, generation of inositol triphosphate and diacylglycerol, mobilization of intracellular Ca 2ϩ , and activation of classical PKC isoforms. We used three different inhibitors of this pathway: PLC␤ inhibitor U73122, calcium chelator BAPTA-AM, and the broad-spectrum PKC inhibitor GF109203X. ERK1/2 activation by apical PAR 2 was abolished by BAPTA-AM, U73122, and GF109203X. In contrast, basolateral ERK1/2 activation was insensitive to GF109203X inhibition but was inhibited by BAPTA-AM and U73122 by ϳ50% (Fig. 6, A-C) . Thus, both basolateral and apical PAR 2 can activate ERK1/2 through G␣q/Ca 2ϩ -mediated pathways, but only the apical PAR 2 pathway requires PKC and relies more heavily on the Ca 2ϩ and PLC␤. PAR 2 can also promote ERK1/2 activation via G protein-independent pathways involving ␤-arrestins (21, 38, 47) . To examine the contribution of ␤-arrestins to basolateral and apical PAR 2 signaling, cells were transfected with a dominant-negative mutant of ␤-arrestin-1 consisting of the clathrin-binding domain (amino acids 319 -418). Transfection of dominant-negative ␤-arrestin (DNarr) inhibited ERK1/2 activation by basolaterally, but not apically, administered 2fAP, suggesting that only the basolateral PAR 2 pool required input from this pathway (Fig. 6D) . A small increase in baseline pERK was also observed in resting DNarr-transfected cells, which may be due to the ability of ␤-arrestins to promote desensitization and internalization of many GPCRs present in epithelial cells, some of which may contribute to the baseline levels of ERK1/2. We conclude that PAR 2 uses multiple mechanisms for ERK1/2 activation in intestinal epithelial cells, and that the apical PAR 2 pool requires PLC␤, Ca 2ϩ , and PKC, while the basolateral PAR 2 requires PLC␤, Ca 2ϩ , and ␤-arrestins.
Previous studies have demonstrated that ␤-arrestin-dependent ERK1/2 activation by PAR 2 and other GPCRs results in sequestration of the activated ERK1/2 at the membrane, where it plays a role in actin cytoskeletal reorganization, rather than transcriptional and proliferative effects associated with nuclear ERK1/2 localization (20, 21, 49, 56) . Thus, we predicted that differential activation of ERK1/2 observed with apical versus basolateral PAR 2 activation might also be associated with different localization patterns. Caco2-BBe monolayers were treated with 2fAP, administered either apically or basolaterally, for 60 min, fixed, and stained with anti-phospho-ERK1/2 and phalloidin (to visualize cell membrane). Upon apical PAR 2 activation, phosphorylated ERK1/2 was predominantly nuclear, while after basolateral addition, phosphorylated ERK1/2 was mostly retained at the membrane and diffusely localized throughout the cytoplasm (Fig. 6E) . Thus, consistent with our previous observations, ␤-arrestin-dependent activation of ERK1/2 was associated with cytosolic/membrane sequestration. To test the possibility that basolateral and apical PAR 2 activation might differentially affect transcription, we examined the effect of 2fAP on activation of the transcription factor AP-1 in monolayers of Caco2-BBe, stably transfected with a A and B: polarized Caco2-BBe monolayers were treated with 2fAP at either the apical (A) or the basolateral (B) surface for 0 -60 min. Representative Western blot analyses performed with anti-phospho-ERK1/2 (pERK, top) and anti-total ERK2 (tERK, bottom) and imaged using the LICOR-Odyssey 2 color Infrared Imaging system are shown. Integrated intensities of each band were determined, pERK levels were normalized to tERK, and fold changes in normalized pERK in treated versus untreated samples were determined. C: bar graph depicting mean Ϯ SE fold increase over baseline in normalized pERK. Baseline is defined as normalized pERK from untreated cells. Statistically significant increases in ERK1/2 activation were determined by ANOVA and differences between experimental groups were determined by two-tailed ttests: *P Ͻ 0.04, **P Ͻ 0.005, n ϭ 4. reporter construct in which luciferase transcription is controlled by a promoter element consisting of three AP-1 binding sites and a TATA box (42) . AP-1 is activated by several signaling pathways including ERK1/2 and JNK (46) . Interestingly, activation of basolateral but not apical PAR 2 resulted in induction of the AP-1-luciferase reporter (Fig. 6F) . Thus, the transcriptional effects resulting from ERK1/2 activation are likely to differ depending on whether apical or basolateral PAR 2 is activated.
Basolateral PAR 2 activation results in activation of cofilin, while apical PAR 2 activation does not. One of the major pathways activated by ␤-arrestins downstream of PAR 2 is the Baseline is defined as normalized pERK observed in vehicle-pretreated cells without 2fAP addition. D: monolayers were transfected with green fluorescent protein (GFP)-tagged dominant-negative ␤-arrestin-1 (DNARR-GFP) or GFP alone, and PAR2-stimulated ERK1/2 phosphorylation was determined as described above. Bar graph depicts mean Ϯ SE fold increase in ERK1/2 phosphorylation over baseline, which is defined as that observed in untreated, GFP-transfected cells. For all graphs, statistically significant increases in ERK1/2 phosphorylation over baseline or between bracketed groups (inhibitor vs. control treated) were determined by two-tailed t-tests: *P Ͻ 0.05, **P Ͻ 0.02, ***P Ͻ 0.005, n ϭ 4. Lanes in A and B were spliced to remove blank lanes (A) and duplicate samples (B) as indicated by white spaces. E: monolayers were untreated (Unt) or treated with apically (AP) and basolaterally (BL) administered 2fAP for 60 min, fixed, and stained with anti-pERK and phalloidin. Arrows indicate nuclear pERK. Arrowheads indicate membrane pERK. F: Caco2-BBe cells were cultured until they were confluent monolayers on Snapwell supports in serum-containing medium. Cells were washed with PBS and transferred to serum-free medium for 16 h. The cells were then treated with PBS vehicle (control; CNT), 1 M 2fAP apical, 1 M 2fAP basolateral, or 500 nM phorbol 12-myristate 13-acetate (PMA) apical and basolateral. Six hours later, cell extracts were prepared and assayed for luciferase activity, expressed in relative light units (RLU). Each bar is the mean Ϯ SE of results obtained with 4 different Snapwells. *Significantly higher than control, as determined by two-tailed t-tests, P Ͻ 0.05. dephosphorylation and activation of the actin filament-severing protein, cofilin (57, 58) . Cofilin promotes rapid actin reorganization by severing existing actin filaments and creating free barbed ends to which actin monomers can spontaneously add. Since only basolateral PAR 2 required ␤-arrestins for ERK1/2 activation, we examined whether it also resulted in cofilin dephosphorylation. Consistent with the findings above, basolaterally administered 2fAP induced cofilin dephosphorylation after 5 and 60 min (Fig. 7, A and C) while apical 2fAP did not (Fig. 7, B and C) . As was previously demonstrated, PAR 2 -stimulated cofilin activation was ␤-arrestin dependent, as transfection of dominant-negative ␤-arrestin blocked cofilin dephosphorylation in response to basolateral PAR 2 activation (Fig. 7D) . A major effect of cofilin actin filament-severing activity is the creation of actin free barbed ends, which promotes remodeling of the actin cytoskeleton. Barbed end formation can be monitored in cells by observing incorporation of labeled actin monomers into lightly permeabilized cells after agonist treatment. Actin monomers will not incorporate into stable filaments; thus they can be used to monitor sites of filament severing. Consistent with cofilin activation, we observe that actin monomers incorporate into cells upon basolateral, but not apical, PAR 2 activation in both cultured Caco2-BBe monolayers (Fig. 7E) . Similar barbed incorporation, colocalizing with the tight junction marker ZO-1, was observed upon 2fAP treatment in isolated intestinal mucosa (Fig. 7F) . We conclude that basolateral PAR 2 is capable of triggering ␤-arrestin-dependent and G protein-dependent signals, while apical PAR 2 does not trigger ␤-arrestin-dependent signaling.
DISCUSSION
Studies on PAR 2 in the intestine have suggested important roles for both apically and basolaterally accessible receptor. For example, luminal introduction of 2fAP to mice colon triggered inflammation, while upon injury and pathogen invasion, mast cells release tryptase to induce inflammation, which presumably involves basolateral and serosal PAR 2 (8, 12, 13, Fig. 7 . Basolateral PAR2 promotes cofilin phosphorylation. A and B: Caco2-BBe monolayers were treated as described in Fig. 4 , and Western blots were analyzed with anti-phospho-cofilin (pcofilin, top) an anti-total-cofilin (tcofilin, bottom). Representative Western blots from cells activated with basolateral (A) or apical (B) 2fAP are shown. C: fold change over untreated was determined as described for phospho-ERK, and mean Ϯ SE fold change over baseline is depicted in the bar graphs. Statistically significant results between treated and untreated cells are indicated or between apical or basolateral phospho-cofilin levels (*P Ͻ 0.05). D: monolayers were transfected with GFP-tagged dominant-negative ␤-arrestin-1 corresponding to amino acids 319 -418, and cofilin dephosphorylation was determined as described above. Samples were run in triplicate, and images were spliced to remove repeated samples. E: Caco-2BBe monolayers were treated with basolateral 2fAP for 5 min, after which cells were lightly permeabilized and free actin barbed ends were labeled with rhodamine-actin monomers (red). Cells were fixed and stained with phalloidin (green) to highlight all cellular actin filaments, and images were collected with a Zeiss LSM510 confocal microscope, ϫ100 objective. Insets: side views of barbed end labeling at tight junctions are shown. Arrows indicate apical surface. F: intestinal mucosa was treated with or without 2fAP for 5 min, after which rhodamine actin labeling was performed as described in D. Tissue was fixed, frozen sections (10 m each) were prepared and stained with phalloidin, and images were collected as described above. 23, 24, 30, 32, 35) . The studies described here demonstrate the existence of spatially and temporally distinct signaling pathways in colonic epithelial cells by apical and basolateral pools of PAR 2 . Both pools of receptor are accessible to agonist activation and promote activation of ERK1/2; however, the mechanisms of ERK1/2 activation differ between apical and basolateral receptors, with only basolateral PAR 2 utilizing a ␤-arrestin-dependent signaling component. Furthermore, only basolateral agonist promoted activation of the actin filamentsevering protein, cofilin, and generation of free actin barbed ends, and redistribution of ZO-1 from the membrane, all processes that might be involved in modulation of tight junctions (Fig. 8) . The use of different signaling mechanisms by apically and basolaterally exposed PAR 2 may allow for a distinct set of cellular events in response to serine proteinases present in the lumen or those released from immune cells present in the serosa at the basolateral surface.
The precise role of epithelial PAR 2 in intestinal inflammation is still unclear, and the identification of separate signaling pathways by different pools of receptor is important for the ultimate understanding of PAR 2 -induced inflammation. Intestinal epithelial cells are the first line of defense against the luminal pathogens, providing a barrier against their invasion of the underlying serosal layer. Factors that affect epithelial barrier function can involve multiple components, including alterations in ion and water secretion, modification of tight junction proteins, and reorganization of actin filaments. Studies have also suggested PAR 2 can lower intestinal epithelial integrity by promoting tight junction reorganization, decreasing R T , and increasing Cl Ϫ secretion (6 -8, 19, 33, 52, 53) . Intestinal Cl Ϫ secretion is regulated by a complex interplay of neurocrine, paracrine, endocrine, and inflammatory signals to provide for optimal luminal fluidity, convective mixing, and flushing in defense against pathogenic intruders (4) . Transient Cl Ϫ secretory responses are triggered by agonists (such as acetylcholine and PAR 2 ) that evoke a mobilization of intracellular Ca 2ϩ (36, 51) , whereas sustained Cl Ϫ secretion is observed in response to agonists (such as vasoactive intestinal peptide) that promote the accumulation of intracellular cAMP (39) . PAR 2 -induced Cl Ϫ secretion was shown here and by others to require activation of basolateral receptors (19, 51) , which is somewhat puzzling because this process is reported to involve some of the same G␣q-dependent events elicited by apical receptors. One explanation is that the mechanisms leading to changes in I sc involve interaction of PAR 2 with receptors or effectors present only at the basolateral surface. For example, many reports have suggested that intestinal Cl Ϫ secretion involves transactivation of EGFR and subsequent activation of ERK1/2, and others have suggested involvement of secreted factors such as PGE2 and substance P (51). Thus, there is likely an additional layer of complexity beyond the differences in G␣q versus ␤-arrestin-dependent signaling described here, and differences in the response to G␣q-dependent signals downstream of apical and basolateral receptors may explain why apical PAR 2 does not promote short-circuit current changes.
In the studies described here, 2fAP added at the basolateral surface led to a mild reduction in transepithelial resistance and redistribution of ZO-1 from the tight junctions, events that might be associated with disruption of barrier function. Only basolateral PAR 2 activated the actin filament-severing protein cofilin and promoted actin assembly at tight junctions, processes previously shown to be ␤-arrestin dependent (57, 58) . However, because both apical and basolateral pools of PAR 2 are able to promote activation of ERK1/2, and apical PAR 2 is Fig. 8 . Model for PAR2 signaling from apical and basolateral surfaces. Apical and basolateral PAR2 would be accessible to different proteolytic agonists, leading to distinct responses. Activation of both PAR2 pools leads to activation of traditional G␣q (which leads to phosphatidylinositol 4,5-bisphosphate hydrolysis into inositol triphosphate and diacylglycerol), mobilization of intracellular Ca 2ϩ , and activation of PKC. ERK1/2 activation by basolateral PAR2 is mediated by both the G␣q-dependent pathway and a ␤-arrestin-dependent pathway but is independent of PKC; the majority of ERK1/2 activated by this pathway does not translocate to the nucleus. PAR2 activated at the apical surface activates ERK1/2 and requires typical G␣q-dependent signals such as Ca 2ϩ and PKC, but it does not require ␤-arrestins. Basolateral but not apical PAR2 is capable of promoting AP-1 activation, which may occur indirectly via phosphorylation of a cytoplasmic protein kinase, such as p90
Rsk . Transcriptional targets of apical PAR2 have not yet been identified but likely involve nuclear ERK1/2. Basolateral but not apical PAR2 stimulated short-circuit current changes, which have been reported to involve Ca 2ϩ , ERK1/2, and transactivation of EGF receptor. Basolateral but not apical PAR2 also activates cofilin via a ␤-arrestin-dependent-pathway, leading to generation of free actin barbed ends at tight junctions (TJ). a more potent activator of early ERK1/2 phosphorylation, this difference is not due to one pool simply being less accessible to activation. Both cofilin activity and ERK1/2-dependent myosin light-chain kinase (MLCK) phosphorylation, have been shown to be important for redistribution of tight junction proteins. Furthermore ␤-arrestins have been suggested to mediate PAR 2 -induced MLCK-phosphorylation (6, 33) . The data shown here suggest that activation of basolateral PAR 2 might play a greater role in tight junction reorganization (Fig. 8) . Thus, it will be interesting to determine whether this pathway is involved in the regulation of epithelial integrity.
Another distinction between the G␣q/Ca 2ϩ and ␤-arrestindependent pathways of ERK1/2 activation by PAR 2 is that the G␣q pathway is associated with gene expression and proliferation, while the ␤-arrestin-dependent pathway is associated with actin reorganization and chemotaxis (21, 25, 26) . Indeed, we observe a primarily nuclear ERK1/2 localization in response to apical PAR 2 activation, while basolaterally activated ERK1/2 was sequestered in the cytoplasm and at the cell membrane. Apical PAR 2 might be exposed to luminal proteases upon damage to the protective mucus layer or released from invading pathogens, and activation of ERK1/2 might generate a transcriptional response appropriate to combating the injury or infection. In contrast, basolateral PAR 2 may respond primarily to proteases present in the bloodstream or released from invading immune and mast cells to promote cytoskeletal reorganization and gene expression/proliferative responses. The two pools of receptors may also promote a distinct set of transcriptional responses. In favor of this hypothesis, basolateral but not apical PAR2 activation resulted in activation of the AP-1 transcription factor. Although cytoplasmic/membrane sequestration of ERK1/2 by ␤-arrestins is typically associated with a decrease in transcription of genes involved in cell cycle progression, some cytosolic targets of ERK1/2, such as the protein kinase p90
Rsk , can translocate to the nucleus to elicit proliferative responses such as AP-1 activation (9 -11) . These responses are also associated with prolonged ERK1/2 activation such as elicited by basolateral receptor (11) . ␤-Arrestin-dependent phosphorylation of p90 Rsk by ERK1/2 has been demonstrated for the angiotensin II type 1A receptor (1) . Furthermore, the small amount of nuclear ERK1/2 (depicted in Fig. 8 , middle cell) may also contribute to the observed activation of AP-1 by phosphorylating Elk-1 (27) .
There are also reports of 2fAP applied to the lumen of the intestine increasing bacterial translocation. We have observed that luminal activation of PAR 2 , as well as activation of apical PAR 2 in cultured monolayers, increases bacterial uptake into epithelial cells (C. Lau and K. A. DeFea, unpublished observations), which may be another mechanism by which apical PAR 2 contributes to PAR 2 -induced inflammation. Future studies addressing the possible differences in gene expression profiles in response to apical versus basolateral PAR 2 activation as well as elucidation of other downstream effects of apical PAR 2 activation are needed to help answer this question.
